- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04803838
The Gut and Oral Bacteria, Atherosclerosis and Ischemic Stroke Study
The main aim of this project is to demonstrate an association between gut and oral microbiota and their metabolites to carotid atherosclerosis and risk of ischemic stroke.
The investigators aim to show that these metabolite levels are diet-dependent (mainly egg yalk and red meat) and associated with specific types of microbiota.
The investigators to assess serum microbiota metabolite levels as a predictor of stroke and plaque progression for patients with carotid atherosclerosis.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The Project will include four studies:
Study 1: (Comparative cross-sectional study) The main objective in this study is to assess if patients with carotid atherosclerosis have increased serum levels gut microbiota dependent metabolites compared to healthy controls.
This study will be done on prospectively collected information already available in our existing database. Approximately 215 patients will be included in this study where collected samples will be analyzed and levels of metabolites quantified. These metabolite levels will be compared to a control group of 70 healthy controls without carotid atherosclerosis (verified by ultrasound), cardiovascular outcome defined as stroke/TIA or vascular death, as well as traditional risk factors for ischemic stroke (diabetes, hypertension, smoking and coronary artery disease).
Study 2: (Comparative cross-sectional study) The aim of this study is to asses if microbiota and microbiota metabolite Levels are Associated With certain types of diet, in particular Rich in red meat and egg yalk.
In this study, 215 patients with ultrasound verified carotid atherosclerosis with or without symptoms of TIA/stroke will be compared to 70 controls. Dietary intake and food habits will be recorded using the SmartDiet questionnaire developed by 'Lipidklinikken Rikshospitalet'. Feces, saliva and blood will be collected analyzed for microbiota and metabolites. Antroprometrics, blood pressure and pulse will be recorded.
In patients undergoing carotid endarterectomy and immunohistochemical analysis will be done.
Study 3: (Comparative cross-sectional study) The aim of this study is to evaluate correlation between the microbiota and microbiota metabolite Levels With other inflammatory markers in blood, as well as known risk factors for stroke and inflammation on imaging modalities (ultrasound, 3-T MRI and PET/CT) .
In this study, 215 patients with ultrasound verified carotid atherosclerosis with or without symptoms of TIA/stroke will be compared to 70 controls.
Patients will undergo investigations with carotid ultrasound, carotid and cerebral MR imaging, blood tests including inflammatory biomarkers. A sub-group of patients will in addition undergo PET/CT imaging of carotid arteries.
Study 4: (Follow up study) The aim of this study is to evaluate the ability of microbiota and microbiota metabolites to predict ischemic stroke in patient With carotid stenosis.
Patients in study 2 and 3 will be followed up after 2 years with repetition of investigations. Findings with serum levels of microbiota metabolites, traditional risk factors and imaging will be correlated to clinical and radiological ischemic events and plaque progression.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Oslo, Norvegia
- Oslo University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
- All patients >18 years with an atherosclerotic carotid stenosis ≥ 50% admitting our department (Dep of Neurology, Rikshospitalet, OUH) as in-patient or out-patient will consecutively be considered for inclusion.
Cooperation With Dep of vascular surgery Akershus University Hospital and Dep of vascular surgery, Aker, OUH, for patients scheduled for thrombendarterectomy.
- Control Group: For study 1: Healthy volonteers For study 2 and 3: Spouses/partners where possible, otherwise matched for age and sex
Descrizione
Inclusion Criteria:
- patients >18 years with an symptomatic og asymptomatic atherosclerotic carotid stenosis ≥ 50% (NASCET criteria)
Exclusion Criteria:
- active infection
- current antibiotic treatment
- autoimmune or autoinflammatory disease
- malignancies
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Patiens
Patients With symptomatic or asymptomatic carotid stenosis (> 50%, NASCET criteria)
|
Nessun intervento
|
Controls
For study 1: Healthy Controls, volunters (mostly blood donors) For study 2 and 3: Spouses/someone living in the same household as the patient.
|
Nessun intervento
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of participants With MRI-confirmed acute ischemic stroke related to increased Levels of serum microbiota-metabolites as assessed by blood tests.
Lasso di tempo: 2 years
|
Blood test (microbiota-metabolites e.g.
TMAO) at study inclusion, carotid ultrasound (carotid plaque assessment and degree of stenosis) and cerebral MRI (evidence of stroke) at follow up
|
2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of participants with progression of carotid stenosis related to increased Levels of serum microbiota-metabolites as assessed by blood tests.
Lasso di tempo: 2 years
|
Blood tests (microbiota metabolites e.g.
TMAO) and carotid ultrasound (plaque assessment and degree of stenosis)
|
2 years
|
Number of participants With increased Levels of microbiota-metabolites related to Diet Rich in red meat and egg yalk as assessed by 'Smart Diet' questionnaire.
Lasso di tempo: At inclusion
|
Blood tests (microbiota metabolites, e.g.
TMAO), dietary questionnaire ('Smart Diet' developed by the department for endocrinology Rikshospitalet)
|
At inclusion
|
Number of participants With increased Levels of microbiota-metabolites related to specific types of microbiota in feces and saliva as assessed by next generation sequencing and 16S RNA.
Lasso di tempo: At inclusion
|
Blood tests (microbiota metabolites e.g TMAO), fecal samples (Next generation sequencing, 16S RNA), saliva samples (Next generation sequencing 16S RNA)
|
At inclusion
|
Number of participants With increased Levels of microbiota-metabolites related to traditional risk factors for ischemic stroke assessed by questionnaire and Medical journal.
Lasso di tempo: At inclusion
|
Blood tests (microbiota metabolites, e.g.
TMAO), questionnaire (Risk factors: hypertension, diabetes mellitus type 2, previous stroke og myocardial infarction, smoking, physical inactivity, Family history)
|
At inclusion
|
Number of participants With increased Levels of microbiota-metabolites related to signs of plaque instability on imaging studies assessed by carotid ultrasound, carotid and cerebral MRI and for a subgroup: carotid PET/CT.
Lasso di tempo: At inclusion
|
Blood tests (microbiota metabolites, e.g.
TMAO), carotid ultrasound (carotid plaque assessment, degree of stenosis), carotid and cerebral MRI (evidence of inflammation and stenosis in carotids, stroke), for a subgroup: carotid PET/CT (evidence of inflammation)
|
At inclusion
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Necrosi
- Malattia cardiovascolare
- Malattie vascolari
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Arteriosclerosi
- Malattie arteriose occlusive
- Ischemia cerebrale
- Infarto
- Infarto cerebrale
- Ictus
- Ictus ischemico
- Ischemia
- Infarto cerebrale
- Aterosclerosi
Altri numeri di identificazione dello studio
- REK 2017/2202
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Nessun intervento
-
RadiancyCompletatoLombalgia cronica da lieve a moderataIsraele
-
Sarah MorrowLawson Health Research InstituteCompletato
-
University of TulsaTerminatoSuicidio, tentatoStati Uniti
-
University of PittsburghReclutamentoDistrofia muscolare di DuchenneStati Uniti
-
Lisbon Institute of Global Mental Health - LIGMHColumbia UniversityReclutamentoDisturbi psicotici | Schizofrenia | Disordine bipolare | Disturbo affettivo schizoidePortogallo
-
Indiana UniversityUniversity of South Florida; National Institute on Minority Health and Health... e altri collaboratoriCompletatoIntervento DECIDE modificato | Trattamento come consueto gruppo di curaStati Uniti
-
University of MichiganNational Institute on Drug Abuse (NIDA)ReclutamentoUso di cannabisStati Uniti
-
Icahn School of Medicine at Mount SinaiReclutamento
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)ReclutamentoProfilassi pre-esposizione all'HIVStati Uniti
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completato